Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for SLE

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.

Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a chronic autoimmune disease.

Intervention/Treatment: The study tests an experimental drug, Deucravacitinib, against a placebo. Deucravacitinib is administered in specified doses on certain days, targeting the treatment of SLE symptoms.

Study Design: This interventional study is randomized with a parallel assignment. It employs a quadruple masking approach, meaning participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary goal is treatment-focused.

Study Timeline: The study began on January 12, 2023, with recruitment currently ongoing. The last update was submitted on August 18, 2025. These dates are crucial for tracking progress and anticipating results.

Market Implications: This study could significantly impact Bristol-Myers Squibb’s stock, particularly if Deucravacitinib proves effective. Success could enhance investor confidence and position the company favorably against competitors in the autoimmune treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.